Ah, the stock market. A bastion of rational exuberance, meticulously calculated risks, and, apparently, a perpetual state of whiplash whenever a certain former (and potentially future) President decides to weigh in. Donald J. Trump, never one to shy away from a pronouncement, has once again graced the financial world with a flurry of policy musings, tariff threats, and strategic declarations, leaving investors to decipher whether to buy, sell, or simply brace for impact. The latest round of market-moving ma ...

In this episode, Andrew and Dave discuss stocks that listeners encounter in their everyday lives. Starting from morning routines involving Keurig coffee and Crest toothpaste, they delve into companies like Dr. Pepper, Keurig Dr Pepper, and Procter & Gamble.The journey continues with an exploration of Johnson & Johnson, various car manufacturers like Ferrari and Tesla, and fast-food giants such as McDonald’s and Domino’s Pizza.They also analyze entertainment stocks like Spotify and Apple, and grocery stores ...

This monthly article series provides a top-down analysis of the healthcare sector, based on industry metrics focusing on value, quality, and momentum. It may also help analyze ETFs such as Health Care Select Sector SPDR ETF (Fred runs the investing group Quantitative Risk & Value where he shares a portfolio invested in quality dividend stocks, and companies at the forefront of tech innovation. Fred also supplies market risk indicators, a real estate strategy, a bond strategy, and an income strategy in close ...

This monthly article series provides a top-down analysis of the healthcare sector, based on industry metrics focusing on value, quality, and momentum. It may also help analyze ETFs such as Health Care Select Sector SPDR ETF (Fred runs the investing group Quantitative Risk & Value where he shares a portfolio invested in quality dividend stocks, and companies at the forefront of tech innovation. Fred also supplies market risk indicators, a real estate strategy, a bond strategy, and an income strategy in close ...

Johnson & Johnson (NYSE:JNJ) said that data from late-stage studies showed that its oral medication, icotrokinra, was more effective compared with Bristol Myers' (BMY) deucravacitinib (Sotyktu) for moderate to severe plaque psoriasis. The studies found that icotrokinra not only met ...

Johnson & Johnson said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two late-stage head-to-head trials. ...

摩根大通将强生的目标价从185美元上调至200美元，维持"中性"评级。(格隆汇) ...

Key TakeawaysDrugmakers have collectively pledged over $350 billion in U.S. investments, with Eli Lilly and Company (LLY) leading with a $5 billion manufacturing plant in Virginia, in response to potential tariff threats.Mitsubishi Corporation (8058.T) and its partners, Anglo American (AAL) and Codelco, finalized a joint mine plan for Chilean copper operations, projecting a $5 billion pre-tax value uplift and an additional 120,000 tonnes of copper production annually.Asia-Pacific stock markets opened lower, ...

Stocks are rallying on the expectation that the Federal Reserve will cut interest rates by 25 basis points in September. That should be positive for corporate earnings. However, those expecting volatility to quiet down may be disappointed. First, lower interest rates may push inflation higher. At the very least, an accommodative Fed policy is likely to keep interest rates above the Fed’s target rate of 2%. Geopolitical events appear to be ratcheting up. Both of those factors explain why central banks contin ...

Johnson & Johnson (NYSE:JNJ) is one of the 10 Unrivaled Stocks of the Next 3 Years. On September 3, Wolfe Research increased the price target for Johnson & Johnson (NYSE:JNJ) from $175 to $195 and kept an Outperform rating. Wolfe Research cited growing confidence in Johnson & Johnson’s (NYSE:JNJ) upcoming talc litigation outcome. This confidence led the firm to use lower weighted average cost of capital (WACC) assumptions in its discounted cash flow analysis. Wolfe Research Lifts PT for Johnson & Johnson ...